These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31071469)

  • 1. Ivermectin: From theory to clinical application.
    Ashour DS
    Int J Antimicrob Agents; 2019 Aug; 54(2):134-142. PubMed ID: 31071469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivermectin in human medicine, an overview of the current status of its clinical applications.
    González P; González FA; Ueno K
    Curr Pharm Biotechnol; 2012 May; 13(6):1103-9. PubMed ID: 22039800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New indications of ivermectin].
    Caumes E; Danis M
    Rev Med Interne; 2001 Apr; 22(4):379-84. PubMed ID: 11586522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis.
    Perez-Garcia LA; Mejias-Carpio IE; Delgado-Noguera LA; Manzanarez-Motezuma JP; Escalona-Rodriguez MA; Sordillo EM; Mogollon-Rodriguez EA; Hernandez-Pereira CE; Marquez-Colmenarez MC; Paniz-Mondolfi AE
    Int J Antimicrob Agents; 2020 Aug; 56(2):106037. PubMed ID: 32479893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of topical ivermectin in dermatology.
    Zargari O; Aghazadeh N; Moeineddin F
    Dermatol Online J; 2016 Sep; 22(9):. PubMed ID: 28329606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Indication of Mectizan in human medicine other than onchocerciasis].
    Richard-Lenoble D
    Sante; 1998; 8(1):84-7. PubMed ID: 9592892
    [No Abstract]   [Full Text] [Related]  

  • 7. African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases.
    Krotneva SP; Coffeng LE; Noma M; Zouré HG; Bakoné L; Amazigo UV; de Vlas SJ; Stolk WA
    PLoS Negl Trop Dis; 2015; 9(9):e0004051. PubMed ID: 26401658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivermectin: a complimentary weapon against the spread of malaria?
    Alout H; Foy BD
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):231-240. PubMed ID: 27960597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interruption of the transmission of Onchocerca volvulus in the Kashoya-Kitomi focus, western Uganda by long-term ivermectin treatment and elimination of the vector Simulium neavei by larviciding.
    Lakwo T; Garms R; Wamani J; Tukahebwa EM; Byamukama E; Onapa AW; Tukesiga E; Katamanywa J; Begumisa S; Habomugisha P; Oguttu D; Byamukama E; Richards F; Unnasch TR; Katabarwa M
    Acta Trop; 2017 Mar; 167():128-136. PubMed ID: 28034767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward.
    Ndyomugyenyi R; Lakwo T; Habomugisha P; Male B
    Ann Trop Med Parasitol; 2007 Jun; 101(4):323-33. PubMed ID: 17524247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivermectin systemic availability in adult volunteers treated with different oral pharmaceutical formulations.
    Ceballos L; Alvarez L; Lifschitz A; Lanusse C
    Biomed Pharmacother; 2023 Apr; 160():114391. PubMed ID: 36804122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of drug combinations in the treatment of schistosomiasis, soil-transmitted helminthiasis, lymphatic filariasis and onchocerciasis.
    Olsen A
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):747-58. PubMed ID: 17481681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DISTRIBUTION AND UTILISATION OF IVERMECTIN (MECTIZAN): A CHEMOTHERAPEUTIC APPROACH TO THE CONTROL OF ONCHOCERCIASIS IN OLD OHAOZARA LGA, EBONYI STATE, EASTERN NIGERIA.
    Okpara EM; Mnaemeka AM; Iyioku UU; Udoh UV
    J Egypt Soc Parasitol; 2015 Dec; 45(3):663-70. PubMed ID: 26939245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study.
    Slater HC; Walker PG; Bousema T; Okell LC; Ghani AC
    J Infect Dis; 2014 Dec; 210(12):1972-80. PubMed ID: 24951826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadening the range of use cases for ivermectin - a review of the evidence.
    Kositz C; Bradley J; Hutchins H; Last A; D'Alessandro U; Marks M
    Trans R Soc Trop Med Hyg; 2022 Mar; 116(3):201-212. PubMed ID: 34323283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.
    Low ZY; Yip AJW; Lal SK
    Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166294. PubMed ID: 34687900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparasitic activity of ivermectin: Four decades of research into a "wonder drug".
    Sulik M; Antoszczak M; Huczyński A; Steverding D
    Eur J Med Chem; 2023 Dec; 261():115838. PubMed ID: 37793327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful elimination of onchocerciasis (river blindness) vectors from isolated foci in two African countries.
    Brattig NW
    Acta Trop; 2009 Sep; 111(3):201-2. PubMed ID: 19619685
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of a half-size ATP-binding cassette transporter gene which may be a useful marker for ivermectin selection in Onchocerca volvulus.
    Ardelli BF; Guerriero SB; Prichard RK
    Mol Biochem Parasitol; 2006 Jan; 145(1):94-100. PubMed ID: 16257066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trop Med Int Health; 2003 Dec; 8(12):1082-92. PubMed ID: 14641843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.